ArticleFrontiers in oncology2025

Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC.

Rodryg Ramlau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.